Localized Resectable Adult Primary Liver Cancer
6
0
0
2
Key Insights
Highlights
Success Rate
40% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
50.0%
3 terminated out of 6 trials
40.0%
-46.5% vs benchmark
17%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
3-Tesla MRI Response to TACE in HCC (Liver Cancer)
Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
Surgery With or Without Hepatic Arterial Chemotherapy in Treating Patients With Liver Cancer
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer